NEURANA PHARMACEUTICALS, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neuranapharma.com
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Phase 3
Completed
- Conditions
- Back Muscle SpasmBack Spasm UpperBack StrainBack PainMuscle SpasmAcute Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 1004
- Registration Number
- NCT04671082
- Locations
- ๐บ๐ธ
Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States
๐บ๐ธAlliance Research Institute, Canoga Park, California, United States
๐บ๐ธLong Beach Clinical Trials Services, Inc, Long Beach, California, United States
A Phase 1 PK Study of Tolperisone in Healthy Subjects
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04465266
- Locations
- ๐บ๐ธ
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04407377
- Locations
- ๐บ๐ธ
CNS Trial, Long Beach, California, United States
๐บ๐ธHassman Research Institute, Berlin, New Jersey, United States
Tolperisone in Acute Muscle Spasm of the Back
Phase 2
Completed
- Conditions
- Acute PainMuscle SpasmLow Back PainBack Spasm Upper BackBack StrainMuscle CrampBack Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 415
- Registration Number
- NCT03802565
- Locations
- ๐บ๐ธ
CITrials, Santa Ana, California, United States
๐บ๐ธPrivate Practice, Plantation, Florida, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
Phase 1
Completed
- Conditions
- Driving Impaired
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03353922
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Network, Long Beach, California, United States
๐บ๐ธNeuroTrials Research, Atlanta, Georgia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath